



FDA ADVISORY
No. 2021-1692

06 JUL 2021

TO: THE GENERAL PUBLIC

SUBJECT: Public Health Warning Against the Purchase and Use of Violative Cosmetic Products as Reported in the ASEAN Post-Marketing Alert System (PMAS):

1. SIFU KUNYIT DAY CREAM
2. SIFU KUNYIT NIGHT CREAM
3. SPARKLE BEAUTY CREAM
4. BB GLOW SOUL CREAM
5. BEAUTY SLEEP TREATMENT CREAM
6. BEAUTYWISE REJUVENATING CREAM
7. BEAUTYWISE REJUVENATING TONER
8. OXY CREAM BY VIPROLABS

The Food and Drug Administration (FDA) warns the public from purchasing and using the following violative cosmetic products, which tested positive for the presence of **HYDROQUINONE, TRETINOIN** and/or **OTHER BANNED INGREDIENTS***, respectively, as reported in the ASEAN Post-Marketing Alert System (PMAS). These ingredients are not allowed to be part of a cosmetic product as per ASEAN Cosmetic Directive (ACD). The table below indicates the particulars of the violative cosmetic products:

Product Details	Product Image/s
<p>1. Sifu Kunyit Day Cream</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: Not Indicated</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	 <p><i>*found to contain Betamethasone</i></p>



Product Details	Product Image/s
<p>2. Sifu Kunyit Night Cream</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: Not Indicated</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	 <p><i>*found to contain Betamethasone</i></p>
<p>3. Sparkle Beauty Cream</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: Thailand</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	 <p><i>*found to contain Betamethasone</i></p>
<p>4. BB Glow Soul Cream</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: Not Indicated</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	
<p>5. Beauty Sleep Treatment Cream</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: China</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	

Product Details	Product Image/s
<p>6. Beautywise Rejuvenating Cream</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: Philippines</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	
<p>7. Beautywise Rejuvenating Toner</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: Philippines</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	
<p>8. Oxy Cream By Viprolabs</p> <p>Manufactured by/Local Company Responsible for Placing the Product in the Market: Not Indicated Country of Manufacture: China</p> <p>Lot/Batch Number: Not Indicated Manufacturing Date: Not Indicated Expiration Date: Not Indicated</p>	 <p><i>*found to contain Clotrimazole</i></p>

The aforementioned products have been tested by the National Pharmaceutical Agency, Malaysia, as part of their post-marketing surveillance activities and results of the laboratory analyses show that these products are not compliant with the technical standards set forth by the ACD.

Hydroquinone, Tretinoin, Betamethasone, and Clotrimazole are not allowed to be part of cosmetic products as these are classified as drug products in the Philippines because of their multiple serious adverse effects when used indiscriminately without medical supervision. Additionally, tretinoin may also cause harm to developing fetus. Women planning to get pregnant or are already expecting are strongly advised to avoid using products containing tretinoin.

In light of the foregoing, the public is advised not to purchase the aforementioned violative products. Moreover, the public is advised to always check if a cosmetic product is notified with the FDA. The FDA website (www.fda.gov.ph) has a *Search* feature which may be used by typing in the name of the product before purchasing.

All concerned establishments are warned not to distribute violative cosmetic products.

All FDA Regional Field Offices and Regulatory Enforcement Units, in coordination with law enforcement agencies and Local Government Units, are requested to ensure that violative products are not sold or made available in the market or areas of jurisdiction.

To report any sale or distribution, complaint and/or adverse event on the use of the violative cosmetic product, the online reporting facility, **eReport** can be accessed at ereport@fda.gov.ph, or call us at the Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR) hotline **(02) 8857-1900 loc. 8113 or 8107**.

Dissemination of this advisory to all concerned is hereby requested.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General

DTN: 20210630103910

